3 November 2026
Oxford BioDynamics Plc
("OBD" or the "Company")
Delayed Settlement Resolved
Oxford BioDynamics Plc (AIM: OBD), the 3D Genomics Company, announced on 10 August 2026 that it had conditionally raised £9.15m through a placing of 9,150,000,000 new ordinary shares (the “Placing Shares”) at a price of £0.001 per Placing Share (the “Placing”). The Placing was approved at a shareholder meeting on 26 August 2026, and the Placing Shares were admitted to trading on AIM on 27 August 2026.
On 1 October 2026 the Company further announced that the proceeds of the Placing were received by the Company at the time of Admission in accordance with the terms of the Placing Agreement, save for £250,000 in respect of 250,000,000 Placing Shares that had still to be received from Vulpes Investment Management (“Vulpes”) and that the Company, Singer Capital Markets and Merlin Partners LLP, who are parties to the Placing Agreement, had agreed to extend the time period under the Placing Agreement for payment to 30 October 2026.
The Company announces the 250,000,000 Placing Shares have now been placed at £0.001 per share with three separate investors, each of whom is an existing shareholder, with Vulpes’ consent. Accordingly, the Placing has now completed and the Company will receive the gross proceeds of £9.15m from the Placing in full.
Capitalised terms used but not otherwise defined in this announcement have the meanings set out in the Circular published on 10 August 2026.
For further information please contact:
|
Oxford BioDynamics Plc Iain Ross, Non-Executive Chairman Richard Compton, CEO Paul Stockdale, CFO |
+44 (0)1865 518910 |
|
Singer Capital Markets – Nominated Adviser and Broker Alex Bond / Russell Cook / Anastassiya Eley |
+44 (0)20 7496 3000 |
|
Merlin Partners LLP – Joint Broker Matthew Clarke |
+44 (0)20 3973 3678 |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD), the 3D Genomics Company, is an international biotechnology company, advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, a cloud-based 3D genomics platform that transforms existing datasets into actionable insights for pharma and biotech partners.
Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch®, which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.
EpiSwitch® Orion is a cloud-based 3D genomics platform that enables pharmaceutical partners to transform standard sequencing data — including legacy whole genome datasets — into actionable discovery insights in hours rather than months. By revealing the genome's 3D architecture, Orion illuminates the 90-95% of disease-associated variants in non-coding regions that traditional NGS and GWAS approaches cannot decipher, bridging the gap between statistical associations and druggable therapeutic targets. The platform is supported by the world's largest curated 3D genomics knowledgebase, featuring over 1.5 billion data points and 15 million high-confidence genomic connections validated across 18,000+ patient samples in more than 40 diseases — a foundation built over nearly two decades that enables partners to identify targets, build predictive classifier models, and design precision interventions at unprecedented speed.
OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.
Since inception, the Company has participated in more than 40 collaborations with pharmaceutical and academic partners, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma America, and has been awarded funding through the US Foundation for the National Institutes of Health's Partnership for Accelerating Cancer Therapies programme and the EU-funded HIPPOCRATES consortium in psoriatic arthritis.
The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com , X (@OxBioDynamics) or LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.